Shoulder Innovations to Report Third Quarter 2026 Financial Results on November 5, 2026

Shoulder Innovations (NYSE: SI) will release Q3 2026 financial results on November 5, 2026, after market close. A conference call is scheduled for 4:30 p.m. ET to discuss the results. The company focuses on shoulder surgical care technology, offering implant systems and related technologies.

Original reporting
Published Oct 15, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Shoulder Innovations to Report Third Quarter 2026 Financial Results on November 5, 2026 — source image
Decision brief

The 30-second read

$SINeutralMed
01

Why it matters

The primary tradable element is the earnings timing and the associated conference call, which can drive pre-positioning and after-hours repricing.

02

Market read

A scheduled Q3 2026 earnings release after the close on Nov. 5, 2026, with a 4:30 p.m. ET conference call.

03

What to watch

Traders may still need to watch for any pre-release updates (e.g., investor presentation, guidance commentary, or analyst notes) that could emerge between now and Nov. 5.

Relevance 4/10Novelty 4/10Timing: after-market-close earnings release scheduled for Nov. 5, 2026

Background

Shoulder Innovations is a commercial-stage medical technology company focused on shoulder surgical care and implant systems.

Company-level read

Ticker impact

$SINeutralMedium confidence
Context

Shoulder Innovations (NYSE: SI) announced it will report Q3 2026 financial results after the close on Nov. 5, 2026 and host a call at 4:30 p.m. ET.

Expected impact

Likely volatility around the Nov. 5 after-hours earnings release as traders position for the quarter’s results and guidance commentary.

Evidence & confidence

The article contains no quarter numbers or guidance changes, only the reporting date/time and call details, which mainly affects timing and positioning rather than fundamentals immediately.

Market effects

Limited sector read-through because the release is only a scheduling notice with no results, guidance, or product/regulatory updates.

Minimal, as it is a single-company event with no macro policy or broad-market data.

Low, since the news is company-specific and does not reference international regulatory or market-wide developments.

Counterpoint

Because the article provides no earnings figures or guidance, it may not materially change expectations versus what the market already anticipates.

Key entities

  • Shoulder Innovations, Inc.

    Commercial-stage medical technology company focused on shoulder surgical care; ticker SI.

Related articles

$SIMedAI 8/10

Shoulder Innovations (SI) Q3 2026 Earnings Call Transcript

Shoulder Innovations reported Q3 2026 net revenue of $16.2M, up 38% YoY, with gross margin at 78.5%. The company raised full-year revenue guidance to $68M-$70M, up 44%-48% YoY. They launched new products, including the InSet Go glenoid implant, and saw strong surgeon adoption and procedural growth. The company expects continued momentum and plans to expand its commercial team.

$SIHigh

Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook

SHOULDER INNOVATIONS, INC. (SI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook 52% Year-to-Date 2026 Revenue Growth Grand Rapids, MI – November 5, 2026 – Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage

$SIMed

22 Humeral Head and Initiates Full Commercial Launch – Ortho Spine News

Shoulder Innovations (NYSE: SI) received FDA 510(k) clearance for its N-22 Humeral Head, a titanium implant for metal-sensitive patients. The company also launched the product commercially. The N-22 Humeral Head complements the N-22 Glenosphere, cleared earlier this year, for use in shoulder arthroplasty procedures. According to the company, this expansion may enhance surgeon relationships and operational centers. Shoulder Innovations focuses on shoulder surgical care, offering advanced implant

$SIMed

Shoulder Innovations Q2 Earnings Call Highlights

Shoulder Innovations (NYSE:SI) reported Q2 gross margin of 78.3% versus 76.2% a year earlier, with SG&A rising to $20.1M and R&D to $3.4M. Net loss narrowed to $10.2M. Cash totaled $99M at June 30. The company expects similar gross margins in 2H 2026 and plans FDA submissions for its robotic platform in 2027.